Please assess the completion status of the following clinical trial:

Trial Title: Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* relapsing remitting and secondary progressive MS patients~* between the ages of 18 and 60~* report cognitive difficulties.~* perform 1 sd or more below cut-off on cognitive screening measure~Exclusion Criteria:~* no history of alcohol/drug abuse or nervous system disorder other than MS~* no sensory impairments that might interfere significantly with cognitive testing~* no developmental history of learning disability or attention-deficit/hyperactivity disorder~* no medical condition other than MS that could substantially affect cognition~* no relapse and/or corticosteroid use within four weeks of assessment;~* no current use of modafinil, armodafinil or other psychostimulants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- armodafinil and placebo (Type: EXPERIMENTAL): All participants will receive one dose of armodafinil and one dose of placebo in a cross-over design

Based on this trial design, predict the completion outcome and termination type (if applicable).